Showing results (11-20 of 51) with videos related to
Sort By:
Pageof 6
Movement Disorders : Official Journal of the Movement Disorder Society|September 29, 2000
The effect of exercise on pharmacokinetics and pharmacodynamics of levodopaI Reuter, S Harder, M Engelhardt, et al.International Journal of Clinical Pharmacology and Therapeutics|August 26, 1998
Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesiaS Harder, H Baas, L Demisch, et al.Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|August 24, 1999
Exercise test in Parkinson's diseaseI Reuter, M Engelhardt, J Freiwaldt, et al.Nuklearmedizin. Nuclear Medicine|June 1, 1989
[SPECT findings in the hemiparkinson syndrome using 99mTc-HMPAO]C Neumann, H Baas, R Hefner, et al.Journal of Neurology|January 1, 1985
Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonismE Schneider, H Baas, P A Fischer, et al.Journal of Neural Transmission|January 1, 1985
Mesulergine and bromocriptine in long-term treatment of advanced parkinsonismH Baas, E Schneider, P A Fischer, et al.Acta Neurologica Scandinavica|March 18, 2006
Drug costs for patients with Parkinson's disease in two different European countriesC Vossius, M Gjerstad, H Baas, et al.British Journal of Clinical Pharmacology|January 1, 1995
Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulationS Harder, H Baas, N Bergemann, et al.Journal of Neural Transmission. Parkinson'S Disease and Dementia Section|January 1, 1995
Lamotrigine in Parkinson's disease--a double blind studyF Zipp, F Bürklin, K Stecker, et al.Clinical Neuropharmacology|May 14, 1998
Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuationsH Baas, S Harder, F Bürklin, et al.Pageof 6